Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Apidra Articles

Highlights from American Diabetes Association meeting

27 June 2011

Highlights of ADA meeting see good results for canagliflozin, Victoza, dapagliflozin, Lantus & Apidra and taspoglutide

28 June 2010

Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations

10 February 2010

Sanofi-Aventis says strong swine flu vaccine sales in 4th quarter will drive higher earnings

30 October 2009

Sanofi launches Apidra SoloSTAR in USA

21 April 2009

Record sales for Sanofi Japan, says president

14 April 2009

Sanofi's Apidra SoloSTAR cleared in the USA

9 March 2009

Sanofi launches Apidra in Canada

2 March 2009

FDA clears Sanofi's Apidra for children

3 November 2008

CHMP removes uncertainty over Tyverb, recommending approval; views other drugs

5 May 2008

Sanofi-Aventis' "insulin city" and SoloSTAR investments paying dividends

25 February 2008

Sanofi-Aventis launches Apidra insulin in USA

13 March 2006

2004 sees a decline in number of NME first launches, with 23 vs 27 in 2003

31 January 2005

Sanofi-Aventis' Apidra cleared in EU

11 October 2004

Positive EU opinion for Aventis' Apidra

14 June 2004

FDA clears Aventis' insulin Apidra

26 April 2004

Aventis files insulin delivery device

23 February 2004

Aventis highlights its late-stage pipeline to justify its stand-alone strategy

16 February 2004

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS